Anti-HGFR/c-MET Polyclonal Antibody (HY196014)

Name: Anti-HGFR/c-MET Polyclonal Antibody
Brand: abinScience
SKU: HY196014
Price: 168 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

50ug
100ug

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue

HY196014

Reactivité des espèces

Human, Mouse, Rat

Applications

ELISA, IHC, WB

Espèce hôte

Rabbit

Clonalité

Polyclonal

Isotype

IgG

Immunogène

E. coli - derived recombinant Human MET/c-Met/HGFR (Val1092-Val1379).

Cible

Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET

Purification

Purified by antigen affinity column.

Numéro d'accès

P08581

Forme

Liquid

Tampon de stockage

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Informations d'utilisation du produit

Application	Dilution
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Stabilité et stockage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Contexte

Hepatocyte growth factor receptor (MET/HGFR) is a ~155 kDa protein. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. MET is the therapeutic target of amivantamab (Rybrevant).

Note

For research use only.

Images

Reférences

Fiche technique